Associated Genetic Biomarkers
PLCB4 is altered in 2.18% of all cancers with melanoma, cutaneous melanoma, conventional glioblastoma multiforme, skin squamous cell carcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations .
The most common alterations in PLCB4 are PLCB4 Mutation (2.14%), PLCB4 G876E (0.11%), PLCB4 E1072K (0.13%), PLCB4 S342L (0.08%), and PLCB4 W548* (0.08%) .
PLCB4 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PLCB4 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PLCB4 status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is PLCB4 Mutation .
Ipilimumab, nivolumab, and pegargiminase are the most frequent therapies in trials with PLCB4 as an inclusion criteria .
Significance of PLCB4 in Diseases
Uveal Melanoma +
PLCB4 is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PLCB4 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.